Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

An update on adjuvant interferon for melanoma.

Richard J Gray1, Barbara A Pockaj, John M Kirkwood

  • 1Division of General Surgery, Mayo Clinic, Arizona, USA. gray.richard@mayo.edu

Cancer Control : Journal of the Moffitt Cancer Center
|March 22, 2002
PubMed
Summary

High-dose interferon therapy significantly improves survival for high-risk melanoma patients, despite potential side effects. This effective adjuvant treatment should be considered standard care for eligible individuals.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

External validation of a model to predict recurrence-free and melanoma-specific survival for patients with melanoma after sentinel node biopsy.

The British journal of surgery·2025
Same author

Imaging Characteristics of and Multidisciplinary Management Considerations for Atypical Ductal Hyperplasia and Flat Epithelial Atypia: Review of Current Literature.

Radiographics : a review publication of the Radiological Society of North America, Inc·2023
Same author

Patient Perspectives and Quality of Life after Breast Reconstruction and the Impact of Subsequent Revisions.

Plastic and reconstructive surgery. Global open·2023
Same author

Postoperative Complication Impact on Quality of Life after Postmastectomy Breast Reconstruction.

Journal of the American College of Surgeons·2023
Same author

A Journey Toward Gender Equity in Medicine.

Mayo Clinic proceedings·2023
Same author

PDJ amplicon in triple negative breast cancer.

Scientific reports·2023

Area of Science:

  • Oncology
  • Dermatology
  • Immunotherapy

Background:

  • High-risk resected melanoma has poor prognoses with high recurrence rates (55-80%) and low survival (25-70%) despite surgical advances.
  • There is a critical need for effective adjuvant therapies to improve outcomes for these patients.

Purpose of the Study:

  • To review the existing literature on interferon as an adjuvant therapy for resected melanoma.
  • To evaluate the efficacy and impact of different interferon dosages on patient survival and disease recurrence.

Main Methods:

  • Systematic literature review focusing on interferon's role in adjuvant melanoma therapy.
  • Analysis of clinical trial data (E1684, Intergroup E1694) examining low-dose versus high-dose interferon regimens.

Related Experiment Videos

Main Results:

  • Low-dose adjuvant interferon showed no significant impact on overall survival and inconsistent effects on disease-free survival.
  • High-dose adjuvant interferon demonstrated improvements in both disease-free and overall survival.
  • While high-dose interferon causes significant morbidity, it yields greater quality-adjusted life years.

Conclusions:

  • Adjuvant high-dose interferon is recommended as standard therapy for high-risk melanoma patients who can tolerate it.
  • This regimen should be utilized as the active control in future clinical trials for alternative adjuvant therapies.